A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0

作者：

Hubbard, Joleen M.

Ahn, Daniel H.

Jones, Jeremy Clifton

Zhu, Mojun

Wittenberger, Kathleen

Csiszovszki, Zsolt

Somogyi, Eszter

Lorincz, Orsolya

Molnar, Levente

Toth, Jozsef

Youssoufian, Hagop

Toke, Eniko Rita

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Mayo Clin, Div Med Oncol, Phoenix, AZ USA

[3] Mayo Clin Florida, Jacksonville, FL USA

[4] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA

[5] TreosBio, Veszprem, Hungary

[6] Treos Bio, Veszprem, Hungary

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3594

引用

页数：1

共 50 条

[1] A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results
Hubbard, J.
Ahn, D.
Jones, J. C.
Jin, Z.
Zhu, M.
Xie, H.
Novo, E.
Graham, R.
Wittenberger, K.
Kremlitzka, M.
Csiszovszki, Z.
Somogyi, E.
Lorincz, O.
Molnar, L.
Toth, J.
Youssoufian, H.
Toke, E. R.
ANNALS OF ONCOLOGY, 2023, 34 : S452 - S452
[2] Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Wittenberger, Kathleen
Molnar, Levente
Lorincz, Orsolya
Somogyi, Eszter
Csiszovszki, Zsolt
Youssoufian, Hagop
Toke, Eniko Rita
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS283 - TPS283
[3] PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201)
Hubbard, Joleen M.
Zemla, Tyler J.
Graham, Rondell P.
Jin, Zhaohui
Zhu, Mojun
Mitchell, Jessica L.
Novo, Elise
Vegh, Eva
Lorincz, Orsolya
Csiszovszki, Zsolt
Kremlitzka, Mariann
Somogyi, Eszter
Molnar, Levente
Toth, Jozsef
Toke, Eniko Rita
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201).
Hubbard, Joleen M.
Zemla, Tyler J.
Graham, Rondell P.
Jin, Zhaohui
Zhu, Mojun
Mitchell, Jessica L.
Novo, Elise
Vegh, Eva
Lorincz, Orsolya
Kremlitzka, Mariann
Somogyi, Eszter
Molnar, Levente
Toth, Jozsef
Toke, Eniko Rita
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 147 - 147
[5] Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
Hubbard, Joleen M.
Toke, Eniko R.
Moretto, Roberto
Graham, Rondell P.
Youssoufian, Hagop
Lorincz, Orsolya
Molnar, Levente
Csiszovszki, Zsolt
Mitchell, Jessica L.
Wessling, Jaclynn
Toth, Jozsef
Cremolini, Chiara
CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2818 - 2829
[6] PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC)
Hubbard, Joleen
Cremolini, Chiara
Graham, Rondell
Moretto, Roberto
Mitchell, Jessica
Wessling, Jaclynn
Toke, Eniko
Csiszovszki, Zsolt
Lorincz, Orsolya
Molnar, Levente
Somogyi, Eszter
Megyesi, Monika
Pantya, Kata
Toth, Jozsef
Pales, Peter
Miklos, Istvan
Falcone, Alfredo
Hubbard, Joleen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[7] Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Fakih, Marwan
Cleary, James M.
Hong, Yong Sang
Kim, Tae-You
Safyan, Rachael A.
Allen, Simon
Bailey, Lorna
Cha, Edward
Lenain, Christelle
Lu, Danny
Schulze, Jochen
Shemesh, Colby S.
Zimmermann, Stefan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
Desai, J.
Hong, Y. S.
Kim, J. E.
Kim, T. W.
Han, S. W.
Bang, Y-J.
Chee, C. E.
Heong, V. Y. M.
Mcree, A.
Chow, L. Q.
Kwak, E. L.
Infante, J. R.
Wallin, J.
Das Thakur, M.
Mwawasi, G.
Foster, P.
Cha, E.
Bendell, J. C.
ANNALS OF ONCOLOGY, 2016, 27
[9] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Bocobo, Andrea Grace
Wang, Renee
Behr, Spencer
Carnevale, Julia C.
Cinar, Pelin
Collisson, Eric Andrew
Fong, Lawrence
Keenan, Bridget P.
Kidder, Wesley Allen
Ko, Andrew H.
Kolli, Kanti Pallav
Kennedy, Megan
Laffan, Angela
Piawah, Sorbarikor
Pollak, Marin
Schwartz, Gabriel
Whitman, Julia
Zhang, Li
Van Loon, Katherine
Atreya, Chloe Evelyn
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Patel, Manish R.
Falchook, Gerald Steven
Hamada, Kensuke
Makris, Lukas
Winkler, Robert E.
Gordon, Gilad Shalag
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)

← 1 2 3 4 5 →